EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Predictive Value of Tumor-Infiltrating Lymphocytes for Neoadjuvant Chemotherapy Among Triple-Negative Breast Cancer

Yuan Xu

International Journal of Biology and Life Sciences · 15.11.2026 · 17 (2) · 32-36

DOI: 10.54097/j931ky70 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biology and Life Sciences, online erschienen am 15.11.2026. Verfasst von Yuan Xu. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with high recurrence risk. Currently, neoadjuvant chemotherapy (NAC) serves as the core therapeutic option for TNBC, which requires effective biomarkers to predict patient prognosis. As the key component of the tumor immune microenvironment (TIME) in the tumor microenvironment (TME), Tumor-infiltrating lymphocytes (TILs) have been confirmed to be correlated with NAC prognosis of TNBC by existing studies, yet most of these studies focus only on patients with early-stage TNBC. In addition, no unified interpretation standard has been established. This review reveals the cellular composition of TILs and the anti-tumor immune mechanisms of TILs subsets, summarizes the internationally quantitative evaluation criteria and published clinical research findings and confirms that stromal tumor-infiltrating lymphocytes (sTILs) can facilitate the prediction of the patients prognosis receiving NAC. This review provides a theoretical support for the application of TILs in the precise stratified treatment of TNBC and the efficacy evaluation of new drugs. At present, in-depth research is still needed to clarify the immune pathway mechanisms of each TIL subset, improve stage-specific research, and standardize the interpretation and assessment of TILs. In future research, artificial intelligence can be applied to optimize detection standards, and large-sample clinical trials should be carried out to further explore the clinical potential of TILs.

Zitieren

APA

Xu, Y. (2026). Predictive Value of Tumor-Infiltrating Lymphocytes for Neoadjuvant Chemotherapy Among Triple-Negative Breast Cancer. International Journal of Biology and Life Sciences, 17(2), 32-36. https://doi.org/10.54097/j931ky70

Vancouver

Xu Y. Predictive Value of Tumor-Infiltrating Lymphocytes for Neoadjuvant Chemotherapy Among Triple-Negative Breast Cancer. International Journal of Biology and Life Sciences. 2026;17(2):32-36. doi:10.54097/j931ky70

BibTeX
@article{Xu2026,
  author = {Xu, Yuan},
  title = {Predictive Value of Tumor-Infiltrating Lymphocytes for Neoadjuvant Chemotherapy Among Triple-Negative Breast Cancer},
  journal = {International Journal of Biology and Life Sciences},
  year = {2026},
  volume = {17},
  number = {2},
  pages = {32--36},
  doi = {10.54097/j931ky70}
}
Kostenlos starten →